BackSELLAS Life Sciences Group Overview

SELLAS Life Sciences Group Total Current Liabilities

SELLAS Life Sciences Group's total current liabilities is $6.5M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$6.46M
6.27% YoYΔ $-432000.00 vs prior year quarter

Peer average

Loading

SELLAS Life Sciences Group Total Current Liabilities History

Loading

SELLAS Life Sciences Group vs. peers: Total Current Liabilities Comparison

Loading

SELLAS Life Sciences Group Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SELLAS Life Sciences Group (SLS) FAQ

SELLAS Life Sciences Group (SLS) currently reports a total current liabilities of $6.5M as of March 2026. That compares with $6.9M in the prior-year period — down 6.3% year over year. Use the charts on this page to explore SELLAS Life Sciences Group's total current liabilities history and peer comparisons.

SELLAS Life Sciences Group's total current liabilities decreased from $6.9M to $6.5M — a 6.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SELLAS Life Sciences Group reported $6.5M in total current liabilities as of March 2026. That compares with $6.9M in the prior-year period — down 6.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $6.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SELLAS Life Sciences Group, and consider following SLS for alerts when major investors trade the stock.

SELLAS Life Sciences Group is classified in the Healthcare sector. On total current liabilities, it currently shows $6.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLS with unrelated industries.